DOYLESTOWN, PA--(Marketwire - July 19, 2011) - Dr. Kohkan Shamsi, Principal at RadMD, led one of the key Biomarker sessions at this year's annual BIO International Convention in Washington DC. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. The Convention also features hundreds of sessions covering biotech trends, policy issues and technological innovations, as well as the world's largest biotechnology exhibition.
In addition to moderating the session, Dr. Shamsi presented along with Dwayne Reives, MD Division of Medical Imaging and Hematology FDA, Larry Schwartz, MD Professor and Chairman of Radiology Columbia University and Medical Center, and Erik Pulkstenis, PhD Director Biostatistics Human Genome Sciences, on the Use of Imaging in Clinical Development: Risk Management Strategies for Site and Independent Image Evaluations.
The presenters expanded on the complexities of using imaging in clinical trials, which require multilevel risk management strategies to ensure regulatory compliant data. The various risk management strategies include prospectively defining image acquisition methodology, image evaluation paradigms, and reader selection and training. Based on these expert presentations, the participants were able to gain insight into the pros and cons of site vs. central read of imaging data in trials, understand the current regulatory environment and learn how to implement risk management strategies when using imaging in clinical trials.
"We are very pleased to have been able to assemble such an esteemed panel to discuss these critical issues of medical imaging in clinical trials," said Dr. Shamsi. "The use of imaging in clinical trials continues to evolve, and we at RadMD remain committed in our efforts to inform and educate around this important topic."
Founded by medical imaging experts Kohkan Shamsi, MD, PhD, and Richard Patt, MD, RadMD (www.rad-md.net) sources clinical experts and provides consulting services for pharmaceutical, biotech and medical device trials and offers both CME-certified and non-CME courses on medical imaging in clinical trials for both on-site and offsite readers. The company's database of 600 readers come from multiple specialties including radiologists, pathologists, oncologists, cardiologists, medical physicists, medical technologists and others. RadMD has sourced readers for trials in cardiovascular, oncology, neurology, musculoskeletal, endocrinology and sports medicine. By facilitating a key component of the clinical trial process, RadMD helps pharmaceutical, biotech and medical device companies reduce clinical development time, thus getting important therapies and diagnostics to the market more quickly.
The BIO international convention is the largest biotechnology meeting globally. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.